Highlights
- 1
- 2Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
- 3Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
Publications
552 publications
Funding
6 grantsView NIH portfolio on RePORTER ↗
Active
4 grants- Co-IHHSN261201500003IPersonalized in vitro models to advance precision health equityNational Cancer Institute · 2024–2027 · via Leidos Biomedical Research
- MPIU24CA264032-01The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor ProfilesNational Cancer Institute · 2021–2026
- Co-IW81XWH-21-1-0762Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity.U.S. Department of Defense · 2021–2026
- KPBCAN 1475808Higher burden of extrachromosomal DNA amplifications drives worse clinical outcomes in African American bladder cancer patientsBladder Cancer Advocacy Network, Inc. · 2025–2026
Completed grants (2)
- Co-INYG 204878-01Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYCNew York Genome Center Inc. · 2020–2024
- PISRA 212316-01SRA Boston GeneBostonGene · 2020–2021Contract
Clinical research
23 studies
Active
4 studies- PINCT06549465A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate CancerPHASE2 · Convergent Therapeutics, Inc. · OPEN TO ACCRUAL (as of 2025)PSMA PET-Positive Castration-Resistant Prostate Cancer
- PINCT05987241MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcerPHASE2; PHASE3 · Alliance for Clinical Trials in Oncology · OPEN TO ACCRUAL (as of 2025)Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma; Muscle Invasive Urethral Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7
- PIEMETPRO: Characteristics, Treatments And Outcomes Of Metastatic Hormone Sensitive Prostate Cancer Patients Progressing Within 6 Months of Beginning Systemic Therapy (ADT or ADT With Docetaxel Or With AR Pathway Inhibitors)Istituto Oncologico della Svizzera Italiana · OPEN TO ACCRUAL (as of 2024)
- PIMolecular Basis of Lineage Plasticity and AR-Independent Prostate CancerWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
Completed & closed trials (19)
- PINCT03375307A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair DefectsPHASE2 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2026)Advanced Bladder Carcinoma; Advanced Genitourinary System Carcinoma; Metastatic Bladder Carcinoma; Metastatic Genitourinary System Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8
- PINCT05928806Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialPHASE2 · Georgetown University · CLOSED TO ACCRUAL (as of 2026)Advanced Renal Cell Carcinoma
- PINCT05293496A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid TumorsPHASE1 · MacroGenics · IRB STUDY CLOSURE (as of 2026)Advanced Solid Tumor; Castration-Resistant Prostatic Cancer; Malignant Melanoma; Pancreatic Ductal Carcinoma; Hepatocellular Cancer; Epithelial Ovarian Cancer; Renal Cell Carcinoma
- PINCT05067140A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate CancerPHASE1; PHASE2 · Arvinas Androgen Receptor, Inc · IRB STUDY CLOSURE (as of 2025)Prostate Cancer Metastatic
- PINCT04709276A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)PHASE2 · Duke University · CLOSED TO ACCRUAL (as of 2025)Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Cancer
- PINCT05617040A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate CancerPHASE1; PHASE2 · Vaccitech (UK) Ltd. · IRB STUDY CLOSURE (as of 2025)Prostate Cancer
- PINCT04191096A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)PHASE3 · Merck Sharp & Dohme Corp · IRB STUDY CLOSURE (as of 2025)Metastatic Hormone-Sensitive Prostate Cancer
- PINCT03888612A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate CancerPHASE1; PHASE2 · Arvinas, Inc. · IRB STUDY CLOSURE (as of 2025)Prostate Cancer Metastatic
- PIPARPi Response Evaluation for Clinical Impact and Scientific Innovation in Oncology: PRECISION RegistryThomas Jefferson University · IRB STUDY CLOSURE (as of 2025)
- PINCT03413995Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)PHASE2 · The Johns Hopkins University · IRB STUDY CLOSURE (as of 2024)Prostate Cancer Metastatic
- PINCT03866382A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)PHASE2 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2024)Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial Carcinoma; Metastatic Bladder Plasmacytoid Urothelial Carcinoma; Metastatic Bladder Sarcomatoid Urothelial Carcinoma; Metastatic Bladder Small Cell Neuroendocrine Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Chromophobe Renal Cell Carcinoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Papillary Renal Cell Carcinoma; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Metastatic Urethral Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Urachal Adenocarcinoma; Urethral Clear Cell Adenocarcinoma
- PINCT05155605The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening PopulationNA · Grail, LLC · CLOSED TO ACCRUAL (as of 2024)Early Detection of Cancer; Cancer
- PINCT04294628Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid TumorsPHASE1 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2024)Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
- PINCT04702737A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate CancerPHASE1 · Amgen, Inc. · IRB STUDY CLOSURE (as of 2023)Neuroendocrine Prostate Cancer
- PINCT04164082Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder CancerPHASE2 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2023)Bladder Flat Urothelial Carcinoma In Situ; Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8
- PINCT04045613An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR AberrationsPHASE1; PHASE2 · Basilea Pharmaceutica, Ltd. · IRB STUDY CLOSURE (as of 2023)Urothelial Carcinoma
- PINCT03606174A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaPHASE2 · Mirati Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2023)Urothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Ureter; Urothelial Carcinoma of the Renal Pelvis and Ureter; Urothelial Carcinoma Urethra
- PINCT03568656An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.PHASE1; PHASE2 · CellCentric LTD · IRB STUDY CLOSURE (as of 2023)Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors
- PINCT02952534TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination DeficiencyPHASE2 · Clovis Oncology, Inc. · IRB STUDY CLOSURE (as of 2020)Metastatic Castration Resistant Prostate Cancer
News mentions
3 mentionsView all WCM news ↗
- PSA Levels Alone May Not Reflect Prostate Cancer GrowthJuly 1, 2026
Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely monitor for cancer progression, according to an analysis led by researchers at Weill Cornell Medicine and Duke University.
- Awards & Honors: October 2025October 21, 2025
Awards, honors and achievements for the month of October.
- Enzalutamide Prolongs Lives of Patients with Nonmetastatic Castration-Resistant Prostate CancerMay 29, 2020
A drug that blocks a male hormone receptor prolonged life by nearly a year compared with the placebo in men with nonmetastatic, castration-resistant prostate cancer, according to the final analysis of the results of an international, multi-center Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.